Desmopressin (DDAVP) serves as a therapeutic agent in type 1 von Willebrand disease (vWD) by promoting the endogenous release of vWF from endothelial cell stores, thereby transiently augmenting plasma vWF and factor VIII levels [46]. The gene discussed is VWF; the disease is von Willebrand disease (hereditary or acquired).